

- IV. Claims 20-25 and 30, drawn to compounds of formula (IV), wherein there is no double bond at the 2- or 4-position of the pyrazolo[3,4-d]pyrimidines and compositions thereof;
- V. Claim 26, drawn to nonstatutory subject matter;
- VI. Claims 27-29, drawn to a method of treating an infection with the compounds of Group (I);
- VII. Claims 27-29, drawn to a method of treating an infection with the compounds of Group (II);
- VIII. Claims 27-29, drawn to a method of treating an infection with the compounds of Group (III); and
- IX. Claims 27-29, drawn to a method of treating an infection with the compounds of Group (IV).

Applicants hereby elect Group III: Claims 14-19, 25, and 30, drawn to compounds of formula (III), wherein a double bond is found at the 2-position of the pyrazolo[3,4-d]pyrimidines and compositions thereof.

Additionally, applicants would like to bring to the Examiner's attention an issue concerning Groups I and II. It is applicants' belief that the Examiner may have intended to include claims 1 to 7 in Group I, instead of claims 1-8. Similarly, it appears to applicants that the Examiner may have intended to include claims 8-13 in Group II, rather than claims 9-13. Applicants respectfully request clarification of this issue.

The above remarks have been made without prejudice to Applicants' right to prosecute any withdrawn subject matter in a timely filed continuing application.

Respectfully submitted,
/John X. Haberman/

Name: John X. Haberman
Dated: March 19, 2008
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451